| Title |
Rituximab-induced regression of CREST-related calcinosis
|
|---|---|
| Published in |
Clinical Rheumatology, November 2012
|
| DOI | 10.1007/s10067-012-2124-z |
| Pubmed ID | |
| Authors |
Dayane Raquel de Paula, Fabiane Barbero Klem, Pedro Gabriel Lorencetti, Carolina Muller, Valderilio Feijó Azevedo |
| Abstract |
About a quarter of sclerodermic patients present calcinosis. However, patients with limited form of the disease are more likely to have calcinosis than patients with diffuse form. We report a case of a 54-year-old female patient with limited cutaneous scleroderma using rituximab (RTX) to treat lung fibrosis and arthritis. Into RTX treatment, she also had a complete resolution of calcinosis in her hands. The patient reported improvement in dyspnea and synovitis after two courses of RTX (four weekly infusions 375 mg/m(2) each). After 7 months of the first infusion, the calcinosis in her fingers had a complete remission, especially the right thumb. Based on current evidences, we discuss the use of rituximab as a promising therapy to treat not only lung disease but also calcinosis in patients with scleroderma. |
Mendeley readers
The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 41 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 7 | 17% |
| Student > Ph. D. Student | 7 | 17% |
| Student > Postgraduate | 5 | 12% |
| Professor > Associate Professor | 3 | 7% |
| Student > Master | 3 | 7% |
| Other | 6 | 15% |
| Unknown | 10 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 56% |
| Agricultural and Biological Sciences | 3 | 7% |
| Nursing and Health Professions | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 2% |
| Engineering | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 11 | 27% |